

Anne Gompel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2210024/publications.pdf>

Version: 2024-02-01

94
papers

4,345
citations

109264

35
h-index

114418

63
g-index

102
all docs

102
docs citations

102
times ranked

4725
citing authors

#	ARTICLE	IF	CITATIONS
1	Impact of vascular liver disease on the menstrual cycle and metabolic status in premenopausal women. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2022, 46, 101756.	0.7	0
2	Micronized progesterone, progestins, and menopause hormone therapy. <i>Women and Health</i> , 2021, 61, 3-14.	0.4	7
3	Hereditary Angioedema with and Without C1-Inhibitor Deficiency in Postmenopausal Women. <i>Journal of Clinical Immunology</i> , 2021, 41, 163-170.	2.0	4
4	Next Generation Sequencing Should Be Proposed to Every Woman With "Idiopathic" Primary Ovarian Insufficiency. <i>Journal of the Endocrine Society</i> , 2021, 5, bvab032.	0.1	30
5	Systemic lupus erythematosus and menopause. <i>Climacteric</i> , 2020, 23, 109-115.	1.1	10
6	Exogenous hormones and hereditary angioedema. <i>International Immunopharmacology</i> , 2020, 78, 106080.	1.7	21
7	Progesterone and endometrial cancer. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2020, 69, 95-107.	1.4	49
8	Ménopause et maladies auto-immunes. <i>La Presse Médicale Formation</i> , 2020, 1, 60-66.	0.1	0
9	Hereditary angioedema: Clinical presentation and socioeconomic cost of 200 French patients. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2019, 7, 328-330.	2.0	3
10	Contraception in cancer survivors " an expert review Part II. Skin, gastrointestinal, haematological and endocrine cancers. <i>European Journal of Contraception and Reproductive Health Care</i> , 2019, 24, 299-304.	0.6	7
11	Hereditary angioedema, emergency management of attacks by a call center. <i>European Journal of Internal Medicine</i> , 2019, 67, 42-46.	1.0	6
12	Estrogen on the breast Yin or Yan?. <i>Maturitas</i> , 2019, 124, 120.	1.0	0
13	Contraception in cancer survivors " an expert review Part I. Breast and gynaecological cancers. <i>European Journal of Contraception and Reproductive Health Care</i> , 2019, 24, 167-174.	0.6	13
14	Modulation of lung cancer cell plasticity and heterogeneity with the restoration of cisplatin sensitivity by neurotensin antibody. <i>Cancer Letters</i> , 2019, 444, 147-161.	3.2	13
15	Type of Combined Contraceptives, Factor V Leiden Mutation and Risk of Venous Thromboembolism. <i>Thrombosis and Haemostasis</i> , 2018, 118, 922-928.	1.8	31
16	Progesterone, progestins and the endometrium in perimenopause and in menopausal hormone therapy. <i>Climacteric</i> , 2018, 21, 321-325.	1.1	24
17	Complete Kisspeptin Receptor Inactivation Does Not Impede Exogenous GnRH-Induced LH Surge in Humans. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2018, 103, 4482-4490.	1.8	5
18	Progesterone, progestins and the breast in menopause treatment. <i>Climacteric</i> , 2018, 21, 326-332.	1.1	29

#	ARTICLE	IF	CITATIONS
19	Cognitive impairment in women with joint hypermobility syndrome/Ehlers-Danlos syndrome hypermobility type. <i>Rheumatology International</i> , 2017, 37, 937-939.	1.5	7
20	Hereditary angioedema with normal C1 inhibitor: clinical characteristics and treatment response with plasma-derived human C1 inhibitor concentrate (Berinert®) in a French cohort. <i>European Journal of Dermatology</i> , 2017, 27, 155-159.	0.3	24
21	Clinical characteristics and response to attack treatment with Berinert® of drug induced angioedema in the French Cohort COBRA.. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, AB236.	1.5	0
22	Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant. <i>Immunity, Inflammation and Disease</i> , 2017, 5, 29-36.	1.3	27
23	Thoracic Endometriosis Syndrome Other Than Pneumothorax: Clinical and Pathological Findings. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1865-1871.	0.7	30
24	Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2017, 471, 521-530.	1.4	10
25	Managing Menopausal Symptoms and Associated Clinical Issues in Breast Cancer Survivors. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3647-3661.	1.8	89
26	Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer. <i>Clinical Cancer Research</i> , 2017, 23, 6516-6528.	3.2	18
27	Screening for familial cancer risk: Focus on breast cancer. <i>Maturitas</i> , 2017, 105, 69-77.	1.0	24
28	Combined Hormonal Contraceptives and First Venous Thrombosis in Young French Women: Impact of Thrombotic Family History. <i>Journal of the Endocrine Society</i> , 2017, 1, 762-771.	0.1	3
29	Proliferation and ovarian hormone signaling are impaired in normal breast tissues from women with <i>BRCA1</i> mutations: benefit of a progesterone receptor modulator treatment as a breast cancer preventive strategy in women with inherited <i>BRCA1</i> mutations. <i>Oncotarget</i> , 2016, 7, 45317-45330.	0.8	14
30	Inhibin A and inhibin B producing ovarian fibrothecoma revealed by suppression of follicle stimulating hormone (FSH) in a post-menopausal woman: report of the first case. <i>Gynecological Endocrinology</i> , 2016, 32, 872-874.	0.7	4
31	Combined estrogenic and anti-estrogenic properties of estetrol on breast cancer may provide a safe therapeutic window for the treatment of menopausal symptoms. <i>Oncotarget</i> , 2015, 6, 17621-17636.	0.8	32
32	Progesterone and Synthetic Progestin Controversies. <i>JAMA Oncology</i> , 2015, 1, 987.	3.4	0
33	New NOBOX Mutations Identified in a Large Cohort of Women With Primary Ovarian Insufficiency Decrease KIT-L Expression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 994-1001.	1.8	48
34	Factors associated with hospital admission in hereditary angioedema attacks: a multicenter prospective study. <i>Annals of Allergy, Asthma and Immunology</i> , 2015, 114, 499-503.	0.5	14
35	Progesterone receptor A predominance is a discriminator of benefit from endocrine therapy in the ATAC trial. <i>Breast Cancer Research and Treatment</i> , 2015, 151, 309-318.	1.1	37
36	Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, 3975-4011.	1.8	589

#	ARTICLE	IF	CITATIONS
37	Are we overestimating the stroke risk related to contraceptive pills?. <i>Current Opinion in Neurology</i> , 2014, 27, 29-34.	1.8	0
38	Antihypertensive Medications and Breast Cancer Risk. <i>JAMA Internal Medicine</i> , 2014, 174, 640.	2.6	1
39	MECHANISMS IN ENDOCRINOLOGY: Epidemiology of hormonal contraceptives-related venous thromboembolism. <i>European Journal of Endocrinology</i> , 2014, 171, R221-R230.	1.9	67
40	The uterine and vascular actions of estetrol delineate a distinctive profile of estrogen receptor $\hat{\pm}$ modulation, uncoupling nuclear and membrane activation. <i>EMBO Molecular Medicine</i> , 2014, 6, 1328-1346.	3.3	96
41	Pneumothorax in Women of Child-Bearing Age. <i>Chest</i> , 2014, 145, 354-360.	0.4	56
42	Suicide HSVtk Gene Delivery by Neurotensin-Polyplex Nanoparticles via the Bloodstream and GCV Treatment Specifically Inhibit the Growth of Human MDA-MB-231 Triple Negative Breast Cancer Tumors Xenografted in Athymic Mice. <i>PLoS ONE</i> , 2014, 9, e97151.	1.1	22
43	Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice. <i>Oncotarget</i> , 2014, 5, 8235-8251.	0.8	35
44	HRT, body mass index and breast cancer risk. <i>Climacteric</i> , 2014, 17, 98-9.	1.1	0
45	Hereditary angioedema with C1 inhibitor deficiency: clinical presentation and quality of life of 193 French patients. <i>Annals of Allergy, Asthma and Immunology</i> , 2013, 111, 290-294.	0.5	88
46	Loss of glucocorticoid receptor activation is a hallmark of BRCA1-mutated breast tissue. <i>Breast Cancer Research and Treatment</i> , 2013, 142, 283-296.	1.1	22
47	Study of Anti-M \hat{A} 1/4llergic Hormone and Its Relation to the Subsequent Probability of Pregnancy in 112 Patients With Systemic Lupus Erythematosus, Exposed or Not to Cyclophosphamide. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2013, 98, 3785-3792.	1.8	51
48	Does hormone replacement therapy (HRT) cause breast cancer? An application of causal principles to three studies. <i>Journal of Family Planning and Reproductive Health Care</i> , 2013, 39, 80-88.	0.9	25
49	Ulipristal acetate does not impact human normal breast tissue. <i>Human Reproduction</i> , 2012, 27, 2785-2798.	0.4	25
50	Management of granulomatous mastitis: a series of 14 patients. <i>Gynecological Endocrinology</i> , 2012, 28, 921-924.	0.7	21
51	International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency. <i>Journal of Allergy and Clinical Immunology</i> , 2012, 129, 308-320.	1.5	207
52	Hormonal contraception in women at risk of vascular and metabolic disorders: Guidelines of the French Society of Endocrinology. <i>Annales D'Endocrinologie</i> , 2012, 73, 469-487.	0.6	29
53	Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review. <i>Breast Cancer Research and Treatment</i> , 2012, 132, 895-915.	1.1	246
54	Glucocorticoid receptor activity discriminates between progesterone and medroxyprogesterone acetate effects in breast cells. <i>Breast Cancer Research and Treatment</i> , 2012, 131, 49-63.	1.1	53

#	ARTICLE	IF	CITATIONS
55	Pregnane progestin contraception in systemic lupus erythematosus: a longitudinal study of 187 patients. <i>Contraception</i> , 2011, 83, 229-237.	0.8	57
56	The potential use of the neurotensin high affinity receptor 1 as a biomarker for cancer progression and as a component of personalized medicine in selective cancers. <i>Biochimie</i> , 2011, 93, 1369-1378.	1.3	81
57	Association of menopause and hormone replacement therapy with large artery remodeling. <i>Fertility and Sterility</i> , 2011, 96, 1445-1450.	0.5	23
58	Glucocorticoid receptor and breast cancer. <i>Breast Cancer Research and Treatment</i> , 2011, 130, 1-10.	1.1	85
59	Catamenial pneumothorax and endometriosis-related pneumothorax: clinical features and risk factors. <i>Human Reproduction</i> , 2011, 26, 2322-2329.	0.4	97
60	Progestogen-Only Contraceptives and the Risk of Acute Myocardial Infarction: A Meta-Analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2011, 96, 1169-1174.	1.8	58
61	Oral Contraceptives and Venous Thromboembolism Consensus Opinion from an International Workshop held in Berlin, Germany in December 2009. <i>Journal of Family Planning and Reproductive Health Care</i> , 2010, 36, 117-122.	0.9	48
62	Antigonadotropic progestogens as contraceptive agents in women with contraindication to combined pill. <i>Hormone Molecular Biology and Clinical Investigation</i> , 2010, 3, 441-447.	0.3	3
63	Progestogen-Only Contraceptives and the Risk of Stroke. <i>Stroke</i> , 2009, 40, 1059-1062.	1.0	88
64	Progestins induce catalase activities in breast cancer cells through PRB isoform: Correlation with cell growth inhibition. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009, 115, 153-160.	1.2	18
65	BRADYKININ RECEPTOR 2 ANTAGONIST (ICATIBANT) FOR HEREDITARY ANGIOEDEMA TYPE III ATTACKS. <i>Annals of Allergy, Asthma and Immunology</i> , 2009, 103, 448.	0.5	68
66	The Neurotensin Receptor-1 Pathway Contributes to Human Ductal Breast Cancer Progression. <i>PLoS ONE</i> , 2009, 4, e4223.	1.1	74
67	Development of a high sensitivity, nested Q-PCR assay for mouse and human aromatase. <i>Breast Cancer Research and Treatment</i> , 2008, 111, 343-351.	1.1	8
68	Focal Subnuclear Distribution of Progesterone Receptor Is Ligand Dependent and Associated with Transcriptional Activity. <i>Molecular Endocrinology</i> , 2007, 21, 14-29.	3.7	44
69	The EMAS 2006/2007 update on clinical recommendations on postmenopausal hormone therapy. <i>Maturitas</i> , 2007, 56, 227-229.	1.0	9
70	Catamenial and Noncatamenial, Endometriosis-related or Nonendometriosis-related Pneumothorax Referred for Surgery. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2007, 176, 1048-1053.	2.5	140
71	Difficult management of recurrent catamenial pneumothorax. <i>Gynecological Endocrinology</i> , 2006, 22, 713-715.	0.7	13
72	Life-Threatening Endometriosis-Related Hemopneumothorax. <i>Annals of Thoracic Surgery</i> , 2006, 82, 726-729.	0.7	24

#	ARTICLE	IF	CITATIONS
73	Updating the EMAS 2004/2005 clinical recommendations on postmenopausal therapy following the recent publications: WHI and Nurses' Health Study. <i>Maturitas</i> , 2006, 55, 1-4.	1.0	8
74	Expression of Neurotensin and NT1 Receptor in Human Breast Cancer: A Potential Role in Tumor Progression. <i>Cancer Research</i> , 2006, 66, 6243-6249.	0.4	121
75	Neurotensin receptor 1 gene activation by the Tcf/ β -catenin pathway is an early event in human colonic adenomas. <i>Carcinogenesis</i> , 2006, 27, 708-716.	1.3	63
76	Climacteric medicine: European Menopause and Andropause Society (EMAS) 2004/2005 position statements on peri- and postmenopausal hormone replacement therapy. <i>Maturitas</i> , 2005, 51, 8-14.	1.0	87
77	Death-Associated Protein Kinase Loss of Expression Is a New Marker for Breast Cancer Prognosis. <i>Clinical Cancer Research</i> , 2004, 10, 3124-3130.	3.2	30
78	Rationale, design and methods of the CASHMERE study+. <i>Fundamental and Clinical Pharmacology</i> , 2004, 18, 131-138.	1.0	19
79	Antiestrogens are pro-apoptotic in normal human breast epithelial cells. <i>International Journal of Cancer</i> , 2003, 105, 607-612.	2.3	40
80	In vitro studies of tibolone in breast cells. <i>Fertility and Sterility</i> , 2002, 78, 351-359.	0.5	60
81	Neurotensin counteracts apoptosis in breast cancer cells. <i>Biochemical and Biophysical Research Communications</i> , 2002, 295, 482-488.	1.0	44
82	Transient secondary amenorrhea in women treated by thalidomide. <i>European Journal of Dermatology</i> , 2002, 12, 63-5.	0.3	18
83	Apoptosis and aging: breast cells and apoptosis. <i>Maturitas</i> , 2001, 38, 39-44.	1.0	5
84	Resistance to induced apoptosis in the human neuroblastoma cell line SK-N-SH in relation to neuronal differentiation. <i>FEBS Journal</i> , 2001, 268, 1352-1362.	0.2	54
85	Endometrial safety and tolerability of AERODIOL® (intranasal estradiol) for 1 year. <i>Maturitas</i> , 2000, 36, 209-215.	1.0	29
86	Massive ovarian haemorrhage complicating oral anticoagulation in the Antiphospholipid Syndrome: a report of three cases. <i>Lupus</i> , 1999, 8, 482-485.	0.8	23
87	Fibrinogen and plasminogen modifications during oral estradiol replacement therapy. <i>Fertility and Sterility</i> , 1997, 68, 449-453.	0.5	40
88	Antagonism between estradiol and progestin on Bcl-2 expression in breast-cancer cells. , 1996, 68, 120-125.		76
89	Estradiol stimulates c-myc proto-oncogene expression in normal human breast epithelial cells in culture. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995, 52, 299-305.	1.2	27
90	Pulmonary Lymphangiomyomatosis. <i>Chest</i> , 1992, 102, 472-476.	0.4	40

#	ARTICLE	IF	CITATIONS
91	Estradiol/Progesterone Interaction in Normal and Pathologic Breast Cells. Annals of the New York Academy of Sciences, 1986, 464, 152-167.	1.8	55
92	Effect of Estradiol and the Synthetic Progestin Promegestone (R5020) on the Proliferation of Human Mammary Cells in Culture. Annals of the New York Academy of Sciences, 1986, 464, 489-492.	1.8	8
93	Contribution of Plasma Androstenedione to 5 α -Androstenediol Glucuronide in Women with Idiopathic Hirsutism. Journal of Clinical Endocrinology and Metabolism, 1986, 62, 441-444.	1.8	44
94	Progestin Effect on Cell Proliferation and 17 β -Hydroxysteroid Dehydrogenase Activity in Normal Human Breast Cells in Culture*. Journal of Clinical Endocrinology and Metabolism, 1986, 63, 1174-1180.	1.8	173